Director dealings

Bioventix plc                                 

                        ("Bioventix" or the "Company")                         

                               Director dealings                               

Bioventix plc (ISDX: BVXP) was notified on 21 October 2013 that on the same
day, the following directors' dealt in ordinary shares of 5 pence each
("Ordinary Shares") in the Group:

Name      Position      Type of     Number of    Price    Ordinary  Percentage
                        transaction  Ordinary      per  shares and of Ordinary
                                       Shares Ordinary      voting  Shares and
                                                 Share rights held      voting
                                               (pence)   following rights held
                                                               the   following
                                                       transaction         the
                                                                   transaction
                                                                              
Ian       Non-Executive Disposal      10,000*    425.0      40,000        0.01
Nicholson Chairman                                                            
                                                                              
Peter     Chief         Disposal    158,824**    425.0     841,176        16.7
Harrison  Executive                                                           

* 5,000 of which were held in the name of his wife

** 29,412 of which were held in the name of his wife

For further information please contact:

Bioventix plc            Chief Executive Officer   Tel: [phone]      
                                                                           
Peter Harrison                                                             
                                                                           
finnCap Ltd              Corporate Finance         Tel: [phone]      
                                                                           
Geoff Nash/Simon Hicks   Corporate Broking                                 
                                                                           
Tom Jenkins                                                                

About Bioventix plc:

Bioventix (www.bioventix.com) specialises in the development and commercial
supply of high-affinity monoclonal antibodies with a primary focus on their
application in clinical diagnostics, such as in automated immunoassays used in
blood testing. The antibodies created at Bioventix are generated in sheep and
are of particular benefit where the target is present at low concentration and
where conventional monoclonal or polyclonal antibodies have failed to produce a
suitable reagent. Bioventix currently offers a portfolio of antibodies to
customers for both commercial use and R&D purposes, for the diagnosis or
monitoring of a broad range of conditions, including heart disease, cancer,
fertility, thyroid function and drug abuse. Bioventix currently supplies
antibody products and services to the majority of multinational clinical
diagnostics companies. Bioventix is based in Farnham, UK and its shares (BVXP)
were admitted to trading on PLUS-SX in April 2010.